IRVINE, Calif., Feb. 15, 2011 /PRNewswire/ — Endologix, Inc.
(Nasdaq:
ELGX), developer of minimally invasive treatments for aortic
disorders, announced today the presentation of the initial clinical
results from the PEVAR Trial at the 2011 iCON (International
Congress of Endovascular Specialists) annual meeting in Scottsdale,
Arizona. Among 33 patients enrolled in the Roll-In phase of the
trial, technical success rates of 97% (access) and 100%
(endovascular repair) have been achieved, with no major adverse
events observed. Patients were discharged from the hospital at an
average of 1.4 days following the procedure.
Participating investigator and presenter Zvonimir Krajcer, MD
(Director, Peripheral Vascular Disease Service, St. Luke’s
Episcopal Hospital at the Texas Heart Institute, Houston, TX)
commented, “In our multidisciplinary practice, a totally
percutaneous approach to endovascular repair with the IntuiTrak
System and Abbott’s Prostar XL closure device has demonstrated
substantial patient benefits as we recently reported in the
Journal of Cardiovascular Surgery. These initial
outcomes in the PEVAR Trial roll-in phase are consistent with the
published single center data, and have served to support initiation
of the randomized phase of the trial. We are very pleased with the
initial results, and look forward to completion of the randomized
trial very soon.”
The PEVAR Trial is the first multicenter, prospective,
randomized trial of totally percutaneous endovascular repair of
abdominal aortic aneurysm and is being conducted at 20 centers in
the United States under an Investigational Device Exemption
approved by the U.S. Food and Drug Administration.
John McDermott, President and Chief Executive Officer said, “We
applaud the PEVAR Trial investigators for their diligence and
dedication to the trial, and commitment to improving patient
outcomes. We
‘/>”/>
